Skip to main content

Table 4 Simulation results on the first and third days showing the percentage of patients achieving target exposures for different doses administered as 3-h extended infusion (EI) after 500-mg IV bolus prior to first dose on day 1

From: Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: implications for empirical therapy against Gram-negative bacteria

TargetfT > 4 μg/mL > 40fT > 4 μg/mL = 100
Regimen with 500 mg IV bolus prior to first dose on day 1Day 1 (N = 24)Day 3 (N = 23)Day 1 (N = 24)Day 3 (N = 23)
1500 mg 8 hourly24 (100%)23 (100%)09 (37.5%)11 (48%)
2000 mg 8 hourly24 (100%)23 (100%)09 (37.5%)14 (61%)
1500 mg 6 hourly24 (100%)23 (100%)15 (63%)20 (87%)
2000 mg 6 hourly24 (100%)23 (100%)16 (67%)23 (100%)
  1. fT > 4 μg/mL > X: plasma meropenem concentration exceeds 4 μg/mL for more than X% of the dosing interval